(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
4 Excellent Remote Headphones of 2024 - 2Grasping the Qualifications Among Separation and Dissolution
- 3Heat Wave Fuels Massive Wildfire In Australia
- 4At UN climate conference, some activists and scientists want more talk on reforming agriculture
- 5A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- 5 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
- A hospital discharged a woman in labor. This lawmaker wants change.
- Top Smoothie Flavor: What's Your Mix?
- Top German court to rule on claims by Wirecard shareholders
- Manual for 6 Hot Brilliant Beds
- Bavarian leader questions Germany's Eurovision participation
- ONE returns to Red Sea with new service
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- Fundamental Home Machines: An Easy to understand Determination Guide
